GLG Announces FDA Issuance of Letter of No Objection for Rebpure 97 Stevia Extract

The GRAS process is a legal and FDA-approved process that allows companies to conduct their own GRAS determinations by consulting with an independent panel of scientists to determine if an ingredient meets the FDA’s criteria for safety.

Sep 15 2010 --- GLG Life Tech Corporation, the vertically-integrated leader in the agricultural and commercial development of high quality stevia, announces the United States Food and Drug Administration (“FDA”) has issued a Generally Recognized as Safe (GRAS) Letter of No Objection (Filing No. GRN000329) for GLG’s highest purity stevia extract Rebpure RA97. In addition, GLG is currently engaged in a comprehensive program to obtain letters of no objection for several of its other highly purified stevia extracts. The Company has filed notices with the FDA following self affirmation for its innovative new blended sweetening system BlendSure as well as its purified stevioside product, PureSTV.

The GRAS process is a legal and FDA-approved process that allows companies to conduct their own GRAS determinations by consulting with an independent panel of scientists to determine if an ingredient meets the FDA’s criteria for safety. To ensure even further confidence in its products, GLG has submitted its dossier to the FDA for review which has resulted in this Letter of No Objection.

Dr. Luke Zhang, Chairman and CEO of GLG stated, “This approval affirms our long-term commitment to provide our customers with the highest quality standards of stevia extracts in the United States and around the world.”